Huaigeng Xu, MD, PhD

Title(s)Postdoctoral Scholar, Urology
SchoolSchool of Medicine
Address35 Medical Center Way, #912A
San Francisco CA 94143
ORCID ORCID Icon0000-0002-4415-1287 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    CiRA, Kyoto University, Kyoto, JapanPhD03/2019Medicine
    Tsuruga Municipal Hospital, Tsuruga, Fukui, Japan03/2015Residency
    Osaka Medical College, Takatsuki, Osaka, JapanMD03/2013Medicine
    Collapse Awards and Honors
    Inoue Foundation for Science 2020Inoue Research Award for Young Scientists
    CiRA 2019 International Symposium2019Best Poster Presentation Award
    CiRA, Kyoto University2019CiRA Encouragement Award
    2018 CiRA Retreat 20182nd Best Oral Presentation Award
    2017 CiRA Retreat2017Best Poster Presentation Award

    Collapse Overview 
    Collapse Overview
    Huaigeng Xu was born in China and grew up in Japan.
    He obtained his MD and PhD in Japan and recently started working at UCSF from March 2020.

    During his PhD, he generated low immunogenicity iPS cells by disrupting HLA genes via CRISPR-Cas9 based genome-editing (Xu et al, Cell Stem Cell, 2019).
    During this work, he learned iPS cell culture and differentiation to blood cells, CRISPR-Cas9 genome editing, immunology (e.g. T cells, NK cells and immune rejection) and basic mouse experiments.

    His personal interest is aging, and his ultimate goal in the future is to solve age-related health problems and manage his longevity.
    He speaks both Japanese and Chinese, and he is willing to interact with a lot of people.

    Collapse Featured Content 
    Collapse Featured Presentations

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
      Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
      Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
      1. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat Biomed Eng. 2023 Jan; 7(1):24-37. Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S. PMID: 36509913; PMCID: PMC9870784.
        View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
      2. Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application. Mol Ther Methods Clin Dev. 2022 Sep 08; 26:15-25. Kitano Y, Nishimura S, Kato TM, Ueda A, Takigawa K, Umekage M, Nomura M, Kawakami A, Ogawa H, Xu H, Hotta A, Takasu N, Tsukahara M. PMID: 35755947; PMCID: PMC9198376.
        View in: PubMed   Mentions: 10  
      3. Optimized electroporation of CRISPR-Cas9/gRNA ribonucleoprotein complex for selection-free homologous recombination in human pluripotent stem cells. STAR Protoc. 2021 Dec 17; 2(4):100965. Xu H, Kita Y, Bang U, Gee P, Hotta A. PMID: 34825222; PMCID: PMC8605105.
        View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
      4. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng. 2021 05; 5(5):429-440. Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, Minagawa A, Ishikawa A, Yano H, Ishi T, Ito R, Goto M, Takahashi R, Uemura Y, Hotta A, Kaneko S. PMID: 34002062.
        View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
      5. Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein. Stem Cell Reports. 2021 Apr 13; 16(4):985-996. Kagita A, Lung MSY, Xu H, Kita Y, Sasakawa N, Iguchi T, Ono M, Wang XH, Gee P, Hotta A. PMID: 33711268; PMCID: PMC8072016.
        View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
      6. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat Commun. 2020 Mar 13; 11(1):1334. Gee P, Lung MSY, Okuzaki Y, Sasakawa N, Iguchi T, Makita Y, Hozumi H, Miura Y, Yang LF, Iwasaki M, Wang XH, Waller MA, Shirai N, Abe YO, Fujita Y, Watanabe K, Kagita A, Iwabuchi KA, Yasuda M, Xu H, Noda T, Komano J, Sakurai H, Inukai N, Hotta A. PMID: 32170079; PMCID: PMC7070030.
        View in: PubMed   Mentions: 110     Fields:    Translation:HumansCells
      7. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports. 2020 01 14; 14(1):49-59. Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, Akasaka M, Nakamura S, Higashi N, Xu H, Matsumoto T, Fujio K, Manz MG, Hotta A, Takizawa H, Eto K, Sugimoto N. PMID: 31883921; PMCID: PMC6962657.
        View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
      8. CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. Nat Commun. 2019 12 06; 10(1):5302. Morisaka H, Yoshimi K, Okuzaki Y, Gee P, Kunihiro Y, Sonpho E, Xu H, Sasakawa N, Naito Y, Nakada S, Yamamoto T, Sano S, Hotta A, Takeda J, Mashimo T. PMID: 31811138; PMCID: PMC6897959.
        View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
      9. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 2019 04 04; 24(4):566-578.e7. Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, Ueda T, Gee P, Nishikawa M, Nomura M, Kitaoka F, Takahashi T, Okita K, Yoshida Y, Kaneko S, Hotta A. PMID: 30853558.
        View in: PubMed   Mentions: 213     Fields:    Translation:HumansAnimalsCells
      10. Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles. Biochem Biophys Res Commun. 2018 11 10; 505(4):1097-1102. Zhitnyuk Y, Gee P, Lung MSY, Sasakawa N, Xu H, Saito H, Hotta A. PMID: 30316514.
        View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
      11. Site-specific randomization of the endogenous genome by a regulatable CRISPR-Cas9 piggyBac system in human cells. Sci Rep. 2018 Jan 10; 8(1):310. Ishida K, Xu H, Sasakawa N, Lung MSY, Kudryashev JA, Gee P, Hotta A. PMID: 29321585; PMCID: PMC5762678.
        View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
      12. Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy. Stem Cells Int. 2017; 2017:8765154. Gee P, Xu H, Hotta A. PMID: 28607562; PMCID: PMC5451761.
        View in: PubMed   Mentions: 23  
      Huaigeng's Networks
      Concepts (84)
      Derived automatically from this person's publications.
      Similar People (60)
      People who share similar concepts with this person.
      Same Department
      Search Department